Treatment of Nx-Ob-ZSF1 rats with FG-2216 improved two secondary cardiac endpoints of the renal study: interstitial fibrosis and plasma concentration of the marker of cardiac hypertrophy NT pro-BNP. This evidence concerns the gene NPPB and cardiac hypertrophy.